Skip to main content
OpenTrials
Completed

NCT Number: NCT05053724

Efficacy of the "Start to Move" Protocol on Functionality, Delirium and Acquired Weakness in ICU

Background: ICU hospitalization is associated with loss of strength, functionality and delirium. The "Start to Move protocol" demonstrated efficacy in improving and minimizing such effects.

Aim: To evaluate the effectiveness of the "Start to move protocol" compared with conventional treatment in ICU subjects on functionality, weakness acquired in the Intensive Care Unit (ICU-AW), incidence of delirium, days of invasive mechanical ventilation (IMV), ICU stay and 28-day mortality.

Methods: Randomized controlled clinical trial. Including adults ≥15 years with IMV >48 hours, randomized into Start to move and conventional treatment groups.Functionality, ICU-AW incidence, delirium incidence, IMV days, ICU stay and mortality-28 days were analyzed.

Completed

Looking for future studies?

Notify Me

Key information

Age range

15 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Sebastián Eduardo Soto López

Santiago, Santiago Metropolitan, 8240000, Chile

About this study

Introduction:

Individuals hospitalized in Intensive Care Units are subjected to a prolonged state of rest and to various factors that directly or indirectly affect the muscular and organic structure, which can result in ICU-acquired weakness (ICU-AW) and a limitation in functional performance.

These factors can be divided into metabolic, pharmacological and organic, where sustained hyperglycemia, corticosteroid use, sedation-analgesia, neuromuscular blockade and multiorgan failure associated with sepsis or septic shock stand out. This state translates into a direct loss of muscle mass, specifically of type II fibers, physiologically explained by an increase in the myosin protein degradation process, a decrease in protein synthesis and an increase in proinflammatory cells that favor the weakness of the critically ill patient.

Brower et al. studied that the effects of prolonged rest produce a deconditioning and atrophy of the musculature. After 14 days of immobilization, young people and adults are exposed to a 9% loss of quadriceps muscle mass, which translates into a loss of muscle strength of up to 27%.In subjects subjected to invasive mechanical ventilation, it has been shown that the cross-sectional area of the quadriceps muscle can decrease up to 12.5% in the first week of their stay in the ICU, which can increase up to 15.7% if they present multiorgan failure versus a 3% loss in subjects with single organ failure.

ICU-AW and loss of function are also directly related to the prolonged use of sedoanalgesia, neuromuscular blockade and a higher incidence of delirium in the ICU. The presence of delirium is related to low participation in physical therapies, either by decreased cooperation and/or psychomotor agitation, thus directly influencing muscle status and subsequent functional recovery.

Brummel et al. report that delirium is common in the ICU, affecting between 60-80% of subjects undergoing IMV and between 20-50% of subjects on noninvasive mechanical ventilation, increasing the risk of removal of invasive elements, accidental extubations and the need for physical restraints that may delay the onset of functional recovery.

To demonstrate the consequences of prolonged rest and quantify ICU-AW, the Medical Research Council (MRC) assessment scale is used, a validated tool which analytically measures the strength of six muscle groups bilaterally with a score of 30 points per hemibody, obtaining a total of 60 points. A score of 48 points or less determines the presence of ICU-AW.

On the other hand, the validated Functional Status Scale - Intensive Care Unit (FSS-ICU), which measures functional milestones with a score between 0 and 35 points, is commonly used to assess the functionality of the critically ill patient 12.

The aim of our study is to evaluate the effectiveness of the Start to move protocol compared to conventional ICU treatment on functionality, ICU-Aw, incidence of delirium, days of mechanical ventilation, ICU stay and 28-day mortality, Clínica Ensenada 2018 - 2019.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects admitted to ICU
  • Adults ≥15 years
  • IMV requirement >48 hours

Exclusion criteria

  • Neuromuscular disease
  • Psychiatric history (attempted autolysis, schizophrenia, senile dementia or others, who due to their condition are unable to follow simple orders, which could bias the assessment and functional treatment)
  • Limb amputation
  • Pregnancy
  • Cardiorespiratory arrest with severe hypoxic-ischemic brain damage
  • Total dependence prior to hospitalization, according to Barthel index (<20 points);
  • Subject without consenting to participate in the study.

Treatment and study plan

Star to move Protocol

Other

Progressive physical therapy according to the Gosslink protocol called "Start to move".

Primary outcomes

  1. Change of ICU-acquired weakness

    Time frame: It is measured in the first 24 hours of the awakening phase of the patient in the 24 hours prior to discharge from the ICU.

    ICU-AW was measured through the MRC scale of 60 points, where scores below 48 points indicate ICU-AW and more than 48 points the greater the strength of the subject.

  2. Change of Functionality of the Critically Ill Patient (Intra-hospital)

    Time frame: It is measured in the first 24 hours of the awakening phase of the patient in the 24 hours prior to discharge from the ICU.

    Through the FSS-ICU evaluation scale, a score of 0 to 35 points is made to evaluate the motor function of the critical patient, where the higher the score, the greater the subject's functionality.

  3. Change of Functionality of the Critically Ill Patient (pre-hospitalization)

    Time frame: It is measured in the first 24 hours of the awakening phase of the patient in the 24 hours prior to discharge from the ICU.

    Evaluation of the Barthel index of a family member, of the baseline state of the patient, before hospitalization. The total score is 100 points, the higher the score, the better the patient's baseline functionality.

  4. Change of Delirium

    Time frame: It is measured in the first 24 hours of the awakening phase of the patient in the 24 hours prior to discharge from the ICU.

    It is measured using the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) scale to determine the presence of delirium. It does not have a score, if it meets criteria the subject will have delirium.

Secondary outcomes

  1. ICU stay (days)

    Time frame: It is measured in the 24 hours prior to discharge from the ICU.

    Number of days hospitalized in ICU, up to 45 days. From the date of admission to the ICU until the departure from the ICU.

  2. Days of invasive mechanical ventilation (IMV)

    Time frame: It is measured in the 24 hours prior to discharge from the ICU.

    Number of days of invasive mechanical ventilation during hospitalization, up to 45 days. From the day of intubation until weaning from invasive mechanical ventilation.

  3. Mortality at 28 days, post ICU discharge

    Time frame: Measured at 28 days post ICU discharge.

    The patient's death is verified according to the medical record (during hospitalization) or through a telephone number to a family member (outside the hospital).

Sponsors and collaborators

Lead sponsor

Hospital Felix Bulnes

Other

Registry information

Official study title

Efficacy of the "Start to Move" Protocol on Functionality, Delirium and Acquired Weakness in ICU. Randomized Clinical Trial.

Acronym: STM

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Sep 22, 2021
Registry last updated
Sep 22, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.